The efficacy of platinum with PARP inhibitors has also been supported by clinical trials, which have demonstrated improved pathological complete response in triple negative breast cancer and improved PFS in ovarian cancer [106, 107]. Here, PARP1 is linked to triple-negative breast carcinoma.